BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Respiratory viruses (RSV, influenza, COVID-19) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for respiratory syncytial virus: 68 (30 sponsors; 23 newly posted in the last 180 days, 7 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 22.8, rank 18 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 17, Phase 2 23, Phase 3 15, Phase 4 1, N/A 11.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pfizer PFE15NA 8, P3 764
GlaxoSmithKline6P3 3, P2 321
Guangzhou Patronus Biotech Co., Ltd.4P1 2, P3 1, P2 110
MAXVAX Biotechnology Limited Liability Company4P2 1, P3 1, P1 1, NA 110
Enanta Pharmaceuticals, Inc ENTA2P2 1, P3 111
Kexing Biopharm Co., Ltd.1P3 100
Shanghai Ark Biopharmaceutical Co., Ltd. new entrant1P3 110
Sanofi SNY6P4 1, P2 2, P1 2, NA 121
Shenzhen Shenxin Biotechnology Co., Ltd3P2 1, P1 201
AstraZeneca AZN2P2 1, NA 111
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. new entrant2P2 1, P1 120
ModernaTX, Inc.2P1 210
Shanghai Institute Of Biological Products2EARLY_P1 1, P2 102
Suzhou Abogen Biosciences Co., Ltd.2P2 1, P1 100
Biothervax SpA new entrant1P2 110
Blue Lake Biotechnology Inc.1P2 100
Clover Biopharmaceuticals AUS Pty CBPHF1P2 100
Clover Biopharmaceuticals USA, LLC CBPHF1P1 100
CSPC Megalith Biopharmaceutical Co.,Ltd. new entrant1P1 111
CSPC Ouyi Pharmaceutical Co., Ltd. new entrant1P2 110
EuBiologics Co.,Ltd1P1 100
Immorna Biotherapeutics, Inc.1P1 100
NextCell Pharma Ab1P1 101
PEACHES BIOTECH1P2 100
Pulmotect, Inc.1P2 101

New-entrant sponsors: Shanghai Ark Biopharmaceutical Co., Ltd., Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Biothervax SpA, CSPC Megalith Biopharmaceutical Co.,Ltd., CSPC Ouyi Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Azidus BrasilNCT06817096 Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and InfluenzaCovid 19; Influenzanot yet recruiting340
2026-12 est.P2Traws Pharma, Inc. TRAWNCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaInfluenzaactive not recruiting105
2026-12 est.P2Enanta Pharmaceuticals, Inc ENTANCT07482657 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirRSV Infection; RSV; Respiratory Syncytial Virus (RSV)recruiting150
2026-12-01 est.P1/P2Sanofi SNYNCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain Pandemic Influenza Immunization; Healthy Volunteersactive not recruiting720
2026-12-01 est.P2/P3HealthBio, Inc.NCT06974084 A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of MaraLong COVIDnot yet recruiting252
2026-12-30 est.P2ShionogiNCT07214571 A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseRespiratory Syncytial Virus Infectionsrecruiting192
2026-12-31 est.P2GeoVax, Inc. GOVXNCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerCOVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myelactive not recruiting63
2027-01-12 est.P2GlaxoSmithKlineNCT07092865 A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following RRespiratory Syncytial Virus Infectionsactive not recruiting168
2027-01-18 est.P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 YeaHuman Metapneumovirus Immunization; Respiratory Syncytial Virus Immunizationactive not recruiting1530
2027-01-25 est.P3Pfizer PFENCT07653100 A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFRespiratory Syncytial Virus (RSV)recruiting540
2027-01-28 est.P3ModernaTX, Inc.NCT07496450 A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsInfluenzaactive not recruiting4050
2027-02-03 est.P2InventVacc Biologicals Inc.NCT07743008 Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate VaccineHaemophilus Influenzae; Haemophilus Influenzae Type aactive not recruiting47

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-10-01FDA AdComheldAdCom 2026-10-01: Vaccines and Related Biological Products Advisory Committee
2026-06-18FDA AdComheldAdCom 2026-06-18: Vaccines and Related Biological Products Advisory Committee
2026-05-28FDA AdComheldAdCom 2026-05-28: Vaccines and Related Biological Products Advisory Committee
2026-03-12FDA AdComheldAdCom 2026-03-12: Vaccines and Related Biological Products Advisory Committee

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Traws Pharma, Inc. TRAWNCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelInfluenzanot yet recruiting165
2026-10-02 est.P1/P2PEACHES BIOTECHNCT06684379 Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-CoSARS-CoV-2; Influenza, Human; Respiratory Syncytial Virus Infections; Respiratory Distress Syndrome;recruiting50
2026-10-01P1/P2AstraZeneca AZNNCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)RSV Respiratory Syncytial Virusactive not recruiting164
2026-10 est.P1/P2Aramis Biotechnologies Inc.NCT07291635 Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza VaccineInfluenzaactive not recruiting728
2026-10 est.P2ImmunityBio, Inc. IBRXNCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19.Long COVIDrecruiting20
2026-09-30 est.P2Shanghai Institute Of Biological ProductsNCT07327398 Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveInfluenzanot yet recruiting1200
2026-09-30 est.P3GlaxoSmithKlineNCT06534892 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age Respiratory Syncytial Virus Infectionsactive not recruiting10212
2026-09-22P3BioNTech SE BNTXNCT07300839 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCOVID-19; SARS-COV-2 Infectioncompleted5240
2026-09-06 est.P2CastleVax Inc.NCT07215520 Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated AdultsCOVID-19active not recruiting200
2026-09 est.P2Vasomune Therapeutics, Inc.NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Resactive not recruiting60
2026-08-26 est.P2ParagonClinicals Inc.NCT07627815 Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVIDLong COVIDrecruiting82
2026-08-25P3Pfizer PFENCT07543380 A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.Respiratory Syncytial Virus (RSV)completed130
2026-08-24P2GlaxoSmithKlineNCT07204964 A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveInfluenza, Humancompleted971
2026-08-15P3Invivyd, Inc. IVVDNCT07655180 Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineCOVID-19completed210
2026-08-06P2BioVie Inc. BIVINCT06847191 NE3107 in Adults With Neurological Symptoms of Long COVIDLong COVIDcompleted203
2026-08-01 est.P3Jiangxi Kvvit Pharmaceutical Co., Ltd.NCT07113392 A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for SuspensionInfluenzanot yet recruiting144
2026-08 est.P3Invivyd, Inc. IVVDNCT07298434 Study of VYD2311 for the Prevention of COVID-19COVID-19active not recruiting1770
2026-07-31 est.P3MAXVAX Biotechnology Limited Liability CompanyNCT07272434 Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)Respiratory Syncytial Virus (RSV)recruiting25000
2026-07-30 est.P3Pfizer PFENCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not HoCOVID-19recruiting160
2026-07-24P3BioNTech SE BNTXNCT07222384 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe CCOVID-19; SARS-COV-2 Infectioncompleted344
2026-07-24P3ModernaTX, Inc.NCT06067230 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsRespiratory Syncytial Viruscompleted1153
2026-07-20P3GlaxoSmithKlineNCT07220109 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of RespRespiratory Syncytial Virus Infectionsactive not recruiting750
2026-07-10P3BioNTech SE BNTXNCT05543616 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenSARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19completed4338
2026-06-26P3Sinovac Biotech Co., Ltd SVANCT07211152 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenInfluenzacompleted150
2026-06-15P2CyanVac LLCNCT06742281 A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsCOVID-19completed432
2026-06-01 est.P1/P2Gylden Pharma LtdNCT05633446 Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)Coronavirus; SARS-CoV-2 Infection; COVID-19not yet recruiting110
2026-05-26P3SeqirusNCT06087640 A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in AdultsInfluenza, Humancompleted38769
2026-05-25P2ModernaTX, Inc.NCT06143046 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersRespiratory Syncytial Viruscompleted360

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "respiratory syncytial virus"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.